Source comparison
MK-677 Sarcopenia vs Standard Interventions: Evidence Comparison
Sarcopenia treatment guidelines from the European Working Group on Sarcopenia in Older People (EWGSOP2) recommend resistance training and protein supplementation as first-line interventions, with pharmacological options considered only when lifestyle modificat
This comparison does not assign a generated winner or score.
- Sarcopenia treatment guidelines from the European Working Group on Sarcopenia in Older People (EWGSOP2) recommend resistance training and protein supplementation as first-line interventions, with pharmacological options considered only when lifestyle modification fails or is impractical. The question MK-677 sarcopenia research must answer is whether it provides additive benefit beyond standard care, and whether that benefit justifies the cost, monitoring burden, and metabolic risks.
- Resistance Training Alone
- +1.5–2.5kg (contingent on compliance and baseline GH levels)
- Moderate to high. Gait speed, grip strength, chair stands all improve if volume is adequate
- Improves insulin sensitivity, reduces visceral fat, lowers cardiovascular risk
- High. Older adults with mobility limitations struggle with gym access and progressive overload
- Gold standard for sarcopenia. No metabolic downside, but efficacy drops sharply in populations with severely suppressed GH/IGF-1
- Protein Supplementation (1.2–1.6g/kg daily)
- +0.5–1.2kg (depends entirely on training stimulus)
- Minimal if training is absent; moderate when paired with resistance training
- Neutral or slightly beneficial for glucose control; renal monitoring needed in CKD
- Low. Cost and palatability are the main obstacles
- Necessary but insufficient. Protein alone doesn't overcome anabolic resistance in low-IGF-1 states
- MK-677 25mg Daily (without training)
- +1.0–1.5kg lean mass, −0.8–1.2kg fat mass
- Minimal to absent in trials under 12 months; modest improvements in 18–24 month studies
- Increases fasting glucose (+4–8 mg/dL), increases fasting insulin, mild fluid retention common
- Moderate. Daily oral dosing is simple, but cost and glucose monitoring add friction
- Hormonal restoration without mechanical stimulus produces body composition changes but limited functional benefit. Best as adjunct to training
- MK-677 + Resistance Training
- +2.0–3.2kg (synergistic effect documented in multiple trials)
- Moderate to high. Combined intervention outperforms either alone in gait speed and TUG test
- Same glucose concerns as MK-677 alone; training partially offsets insulin resistance
- Moderate. Adherence to both components required; dropout rates higher than training alone
- Most evidence-supported pharmacological approach for severe sarcopenia when training alone has failed. Requires metabolic monitoring
- Testosterone Replacement (men only)
- +1.8–3.5kg lean mass (dose-dependent)
- High. Strength and physical performance improve consistently
- Increases haematocrit, may worsen sleep apnoea, prostate monitoring required
- Low for injections, moderate for gels
- Effective for hypogonadal men but limited to male populations and requires ongoing PSA surveillance
- The comparison reveals that MK-677 occupies a narrow therapeutic niche. It's most defensible when baseline IGF-1 is severely suppressed (below 100 ng/mL), when injectable GH or testosterone aren't viable options, and when the patient can commit to structured resistance training. Used alone, MK-677 sarcopenia protocols produce measurable body composition improvements but don't consistently translate to functional gains within the first year. Used alongside training, the combination outperforms either intervention in isolation, but the metabolic trade-offs require informed decision-making.